Literature DB >> 20716960

Deciphering the anticancer mechanisms of sunitinib.

Sumanta Kumar Pal1, Robert A Figlin, Hua Yu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20716960      PMCID： PMC3093811          DOI： 10.4161/cbt.10.7.13130

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  15 in total

1.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors:  George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

2.  Inhibition of human mammary and prostatic cancers by adrenalectomy.

Authors:  C HUGGINS; D M BERGENSTAL
Journal:  Cancer Res       Date:  1952-02       Impact factor: 12.701

3.  RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.

Authors:  Joyce A O'Shaughnessy; Adam M Brufsky
Journal:  Clin Breast Cancer       Date:  2008-08       Impact factor: 3.225

Review 4.  Sunitinib: from rational design to clinical efficacy.

Authors:  Laura Q M Chow; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

5.  SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.

Authors:  E L Mayer; S Dhakil; T Patel; S Sundaram; C Fabian; M Kozloff; R Qamar; F Volterra; H Parmar; M Samant; H J Burstein
Journal:  Ann Oncol       Date:  2010-05-23       Impact factor: 32.976

6.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

7.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Authors:  Harold J Burstein; Anthony D Elias; Hope S Rugo; Melody A Cobleigh; Antonio C Wolff; Peter D Eisenberg; Mary Lehman; Bonne J Adams; Carlo L Bello; Samuel E DePrimo; Charles M Baum; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-03-17       Impact factor: 44.544

8.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

Review 9.  HER2 targeted therapy in breast cancer...beyond Herceptin.

Authors:  Sumanta Kumar Pal; Mark Pegram
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

10.  Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Authors:  James H Finke; Brian Rini; Joanna Ireland; Patricia Rayman; Amy Richmond; Ali Golshayan; Laura Wood; Paul Elson; Jorge Garcia; Robert Dreicer; Ronald Bukowski
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531
View more
  4 in total

1.  Cardiotoxicity associated with targeted cancer therapies.

Authors:  Z I Chen; D I Ai
Journal:  Mol Clin Oncol       Date:  2016-03-03

2.  Kinase inhibitors in the treatment of immune-mediated disease.

Authors:  Apostolos Kontzias; Arian Laurence; Massimo Gadina; John J O'Shea
Journal:  F1000 Med Rep       Date:  2012-03-01

3.  Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.

Authors:  Edmund Chinchar; Kristina L Makey; John Gibson; Fang Chen; Shelby A Cole; Gail C Megason; Srinivassan Vijayakumar; Lucio Miele; Jian-Wei Gu
Journal:  Vasc Cell       Date:  2014-06-01

Review 4.  Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.

Authors:  Sungkyoung Kim; Wenping Ding; Lian Zhang; Wei Tian; Siyu Chen
Journal:  Onco Targets Ther       Date:  2014-05-12       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.